Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Discovery of Lenacapavir: First-in-Class Twice-Yearly Capsid Inhibitor for HIV-1 Treatment and Pre-exposure Prophylaxis.
Journal: Journal of medicinal chemistry
Published: October 01, 2025
Impact of HIV-1 capsid polymorphisms on viral infectivity and susceptibility to lenacapavir.
Journal: mBio
Published: April 17, 2025
Long-acting lenacapavir acts as an effective preexposure prophylaxis in a rectal SHIV challenge macaque model.
Journal: The Journal of clinical investigation
Published: December 20, 2022
Long-acting capsid inhibitor protects macaques from repeat SHIV challenges.
Journal: Nature
Published: June 02, 2021
Clinical targeting of HIV capsid protein with a long-acting small molecule.
Journal: Nature
Published: November 26, 2019
Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile.
Journal: Antimicrobial agents and chemotherapy
Published: July 07, 2016
Rapid In Vitro Evaluation of Antiretroviral Barrier to Resistance at Therapeutic Drug Levels.
Journal: AIDS research and human retroviruses
Published: July 01, 2016
TLR7 Agonist GS-9620 Is a Potent Inhibitor of Acute HIV-1 Infection in Human Peripheral Blood Mononuclear Cells.
Journal: Antimicrobial agents and chemotherapy
Published: June 26, 2016
Exercise performance and peripheral vascular insufficiency improve with AMPK activation in high-fat diet-fed mice.
Journal: American journal of physiology. Heart and circulatory physiology
Published: February 25, 2014
1-(4-Phenylpiperazin-1-yl)-2-(1H-pyrazol-1-yl)ethanones as novel CCR1 antagonists.
Journal: Bioorganic & medicinal chemistry letters
Published: December 05, 2012
Showing 1-11 of 11
Last Updated: 09/26/2026